(PFE) stock has fallen 0.3% over the past week, risen 4.1% over the past month, and added 6.8% across the last year. Wall Street’s analysts are bullish, forecasting a 10.7% increase in PFE over the next twelve months. Pfizer’s shares sit at $25.77, within a 52-week band of $20.92 to $27.69, and investors continue to weigh its generous dividend against sluggish revenue momentum.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Jason Gerberry (BofA) maintained PFE’s price target at $27.00, implying a 4.8% upside from current levels. He reiterated a Hold stance after modest adjustments to 2027-28 revenue projections, citing the company’s inexpensive multiple but limited near-term catalysts. The analyst emphasized that while Pfizer’s yield above 6% offers support, the market wants clearer signals of growth beyond looming loss-of-exclusivity pressures.
Gerberry’s report highlighted the Phase 2b VESPER-3 obesity data, where monthly dosing for PF’3944 seemed viable, reinforcing optimism around Pfizer’s long-acting obesity ambitions. Still, he noted unresolved questions on high-dose efficacy-tox tradeoffs that could shape competitiveness once Phase 3 readouts arrive in 2027. Though he kept a $5 billion nominal forecast for PF’3944, he underscored the need for more pipeline visibility to offset lingering COVID-19 revenue declines.
TipRanks Ranking Metrics: This 4-star analyst ranks #324 out of 11,984, with a 61.73% success rate and a 15.50% average return per rating. Investors tracking Gerberry’s calls may appreciate his balanced perspective: Pfizer’s valuation looks compelling, yet delivery on pipeline promises remains the swing factor for a sustained re-rating.
Never miss a stock rating. Find all the latest ratings on TipRanks’ Top Wall Street Analysts page.